Your browser doesn't support javascript.
loading
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
Wefers, Annika K; Stichel, Damian; Schrimpf, Daniel; Coras, Roland; Pages, Mélanie; Tauziède-Espariat, Arnault; Varlet, Pascale; Schwarz, Daniel; Söylemezoglu, Figen; Pohl, Ute; Pimentel, José; Meyer, Jochen; Hewer, Ekkehard; Japp, Anna; Joshi, Abhijit; Reuss, David E; Reinhardt, Annekathrin; Sievers, Philipp; Casalini, M Belén; Ebrahimi, Azadeh; Huang, Kristin; Koelsche, Christian; Low, Hu Liang; Rebelo, Olinda; Marnoto, Dina; Becker, Albert J; Staszewski, Ori; Mittelbronn, Michel; Hasselblatt, Martin; Schittenhelm, Jens; Cheesman, Edmund; de Oliveira, Ricardo Santos; Queiroz, Rosane Gomes P; Valera, Elvis Terci; Hans, Volkmar H; Korshunov, Andrey; Olar, Adriana; Ligon, Keith L; Pfister, Stefan M; Jaunmuktane, Zane; Brandner, Sebastian; Tatevossian, Ruth G; Ellison, David W; Jacques, Thomas S; Honavar, Mrinalini; Aronica, Eleonora; Thom, Maria; Sahm, Felix; von Deimling, Andreas; Jones, David T W.
Afiliación
  • Wefers AK; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. annika.wefers@med.uni-heidelberg.de.
  • Stichel D; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. annika.wefers@med.uni-heidelberg.de.
  • Schrimpf D; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. annika.wefers@med.uni-heidelberg.de.
  • Coras R; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Pages M; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tauziède-Espariat A; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Varlet P; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schwarz D; Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany.
  • Söylemezoglu F; Department of Neuropathology, Sainte-Anne Hospital, Descartes University, Paris, France.
  • Pohl U; Department of Neuropathology, Sainte-Anne Hospital, Descartes University, Paris, France.
  • Pimentel J; Department of Neuropathology, Sainte-Anne Hospital, Descartes University, Paris, France.
  • Meyer J; Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
  • Hewer E; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Japp A; Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Joshi A; Department of Cellular Pathology, Queen's Hospital BHRUT, Romford, UK.
  • Reuss DE; Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham/University Hospitals Birmingham, Birmingham, UK.
  • Reinhardt A; Department of Neurosciences and Mental Health, Laboratory of Neuropathology, Hospital de Santa Maria (CHULN, EPE), Lisbon, Portugal.
  • Sievers P; Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Casalini MB; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Ebrahimi A; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Huang K; Institute of Pathology, University of Bern, Bern, Switzerland.
  • Koelsche C; Department of Neuropathology, University of Bonn, Bonn, Germany.
  • Low HL; Department of Neuropathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Rebelo O; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Marnoto D; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Becker AJ; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Staszewski O; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mittelbronn M; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Hasselblatt M; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schittenhelm J; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Cheesman E; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • de Oliveira RS; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Queiroz RGP; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Valera ET; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Hans VH; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Korshunov A; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Olar A; Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Ligon KL; Department of Neurosurgery, Queen's Hospital BHRUT, Romford, UK.
  • Pfister SM; Neuropathology Unit, Centro Hospitalar de Universidades de Coimbra, Coimbra, Portugal.
  • Jaunmuktane Z; Neuropathology Unit, Centro Hospitalar de Universidades de Coimbra, Coimbra, Portugal.
  • Brandner S; Department of Neuropathology, University of Bonn, Bonn, Germany.
  • Tatevossian RG; Institute of Neuropathology, University of Freiburg, Freiburg, Germany.
  • Ellison DW; Edinger Institute, Institute of Neurology, University of Frankfurt am Main, Frankfurt, Germany.
  • Jacques TS; Luxembourg Center of Neuropathology (LCNP), Dudelange, Luxembourg.
  • Honavar M; Laboratoire National de Santé (LNS), National Center of Pathology (NCP), Dudelange, Luxembourg.
  • Aronica E; Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Thom M; Department of Oncology (DONC), Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
  • Sahm F; Institute of Neuropathology, University Hospital Münster, Münster, Germany.
  • von Deimling A; Department of Neuropathology, Institute of Pathology and Neuropathology, University Hospital of Tübingen, Tübingen, Germany.
  • Jones DTW; Center for CNS Tumours, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital of Tübingen, Tübingen, Germany.
Acta Neuropathol ; 139(1): 193-209, 2020 01.
Article en En | MEDLINE | ID: mdl-31563982
ABSTRACT
The "isomorphic subtype of diffuse astrocytoma" was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Transactivadores / Proteínas Proto-Oncogénicas / Proteínas Proto-Oncogénicas c-myb / Glioma Tipo de estudio: Prognostic_studies Límite: Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Transactivadores / Proteínas Proto-Oncogénicas / Proteínas Proto-Oncogénicas c-myb / Glioma Tipo de estudio: Prognostic_studies Límite: Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Año: 2020 Tipo del documento: Article País de afiliación: Alemania
...